← Back to guidelines
Cardiology102 papers

Neuronal ceroid lipofuscinosis

Last edited: 4/15/2026

Overview

Neuronal ceroid lipofuscinosis (NCL) encompasses a group of inherited neurodegenerative disorders characterized by lysosomal accumulation of specific storage materials, leading to progressive neurological decline in childhood. Variant late infantile NCL (vLINCL), also known as CLN-5 disease, is distinguished by genetic localization to chromosome 13q22 and shares biochemical features with classical forms, including accumulation of subunit c of mitochondrial ATP synthase 1.

Diagnosis

  • Clinical Presentation: Progressive neurological deterioration, often with characteristic age of onset 1.
  • Biopsy and Immunohistochemistry: Presence of granular storage material in brain tissue, particularly subunit c of mitochondrial ATP synthase and sphingolipid activator proteins (SAPs) 1.
  • Metachromasia: White matter granular material staining metachromatically with toluidine blue in paraffin sections may be observed 2.
  • Management

  • No Specific Curative Treatment: Current management focuses on supportive care to alleviate symptoms 12.
  • Symptomatic Interventions: Addressing seizures with antiepileptic drugs, managing spasticity, and providing physical and occupational therapy 1.
  • Genetic Counseling: Essential for families with affected individuals to understand inheritance patterns and risks 1.
  • Special Populations

  • Pediatrics: Early diagnosis and supportive care are crucial for improving quality of life 1.
  • Comorbidities: Management strategies should consider coexisting conditions such as epilepsy and motor dysfunction 1.
  • Key Recommendations

  • Utilize biopsy and immunohistochemistry to identify subunit c of mitochondrial ATP synthase and SAPs for diagnosis (Evidence: Moderate 1).
  • Implement supportive care measures including symptomatic treatment for seizures and physical therapy (Evidence: Expert opinion 1).
  • Offer genetic counseling to families to understand disease inheritance and implications (Evidence: Expert opinion 1).
  • References

    1 Tyynelä J, Suopanki J, Santavuori P, Baumann M, Haltia M. Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry. Journal of neuropathology and experimental neurology 1997. link 2 Hormia M. Neuronal ceroid-lipofuscinosis and metachromasia. Acta neuropathologica 1980. link

    Original source

    1. [1]
      Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry.Tyynelä J, Suopanki J, Santavuori P, Baumann M, Haltia M Journal of neuropathology and experimental neurology (1997)
    2. [2]
      Neuronal ceroid-lipofuscinosis and metachromasia.Hormia M Acta neuropathologica (1980)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG